Heritage Pharma Labs has acquired a portfolio of 23 abbreviated new drug applications (ANDAs), covering 17 product families, all of which have been previously approved by the U.S. Food and Drug Administration (FDA). Financial terms were not disclosed.   Of the newly acquired products, Heritage and its parent company, Emcure Pharmaceuticals, had previously manufactured most of these products under a supply agreement with a third party, and Heritage plans to launch all of these products into the U...